FDA Approves Updated Pfizer, Moderna COVID-19 Vaccines Targeting Omicron KP.2 on Thursday

Aug 22, 2024, 05:44 PM

The U.S. Food and Drug Administration (FDA) has approved updated COVID-19 vaccines from Pfizer/BioNTech and Moderna on Thursday. These vaccines are designed to target the Omicron KP.2 variant and are expected to be available within days. The approval comes amid a significant summer wave of COVID-19 infections across the United States. The updated vaccines have been granted emergency use authorization and are intended for the 2024 fall and winter vaccination campaign. The Novavax booster is still pending approval.